Impact of CYP2C19 genetic polymorphisms on voriconazole exposure and safety in a Uruguayan hemato-oncologic cohort
This study of a Uruguayan hemato-oncologic cohort demonstrates that while CYP2C19 genetic polymorphisms significantly influence voriconazole exposure and toxicity risks, integrating preemptive genotyping with routine therapeutic drug monitoring is essential for optimizing treatment outcomes in complex clinical scenarios.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a patient with a serious blood cancer receives treatment, their immune system often becomes too weak to fight off common fungal infections. To prevent these potentially life-threatening infections, doctors frequently prescribe a powerful antifungal medicine called voriconazole. This drug is highly effective, but it walks a very fine line. If the amount of the drug in a patient's blood is too low, it cannot stop the fungus from growing. If the amount is too high, the drug itself can become toxic, causing severe side effects like hallucinations, joint pain, or liver damage. The challenge is that every person's body processes this medicine differently. Some people break it down quickly, clearing it from their system before it can do its job, while others break it down slowly, allowing the drug to build up to dangerous levels. This variation is largely determined by a specific gene, known as CYP2C19, which acts as a set of instructions for an enzyme that digests the drug. Because these genetic instructions vary from person to person, finding the right dose is often a matter of trial and error, requiring doctors to constantly check blood levels to ensure safety and effectiveness.
A team of researchers in Uruguay set out to understand how these genetic differences specifically affect patients with blood cancers in their region. They studied a group of 25 adult patients being treated at a university hospital in Montevideo between late 2021 and late 2024. The researchers first looked at the genetic makeup of these patients to see which version of the CYP2C19 gene they carried. They classified the patients into three main groups based on how fast their bodies were expected to process the drug: normal metabolizers, who break it down at a standard rate; intermediate metabolizers, who break it down somewhat slower; and rapid metabolizers, who break it down very quickly. To get a broader picture of the local population, they also analyzed the genes of 157 healthy volunteers, creating a reference group of 182 people to see how common these genetic variations are in Uruguay.
The study revealed that the genetic makeup of the Uruguayan patients closely matched what is seen in other populations, with the majority being normal metabolizers. However, the results highlighted a significant problem with the current way the drug is often prescribed. When the researchers measured the actual amount of voriconazole in the patients' blood just before their next dose, they found that nearly half of the measurements fell outside the safe and effective range. Specifically, 27 percent of the samples showed levels that were too low to be effective, while 19 percent showed levels that were too high and risked causing harm. This high rate of imbalance suggests that relying on a standard dose for everyone is not working well for this group of patients.
The researchers then looked at how the different genetic groups fared. They found that the patients classified as rapid metabolizers indeed had lower levels of the drug in their blood compared to the normal metabolizers, confirming that their bodies were clearing the medication too fast. Interestingly, the intermediate metabolizers did not have significantly different blood levels than the normal group, yet they experienced a higher rate of specific side effects. Two patients in this intermediate group suffered from visual hallucinations and joint pain, and both had very high concentrations of the drug in their blood. This suggests that even if the average drug level looks similar between groups, the intermediate metabolizers might be more sensitive to the drug's toxic effects, or that their bodies handle the drug in a way that creates more risk at certain doses.
Another major finding concerned the liver. Liver function tests showed signs of stress in 60 percent of the patients, but the researchers noted that these changes were usually mild. Crucially, they observed that almost every patient with elevated liver enzymes was also taking other medications that are known to be hard on the liver. This indicates that the liver issues were likely caused by a combination of the antifungal drug and other treatments, rather than the antifungal alone. The study found no clear link between the highest levels of voriconazole and the most severe liver damage, suggesting that the liver problems were a complex result of multiple factors rather than just the amount of the drug in the blood.
The researchers concluded that while checking a patient's genes is a powerful tool for predicting how they might process voriconazole, it is not enough on its own. The study showed that knowing a patient's genetic type helps identify those at risk, such as the rapid metabolizers who might need a higher dose or a different drug entirely, and the intermediate metabolizers who might be at higher risk for side effects. However, because so many patients still ended up with drug levels that were too high or too low, the researchers emphasized that genetic testing must be paired with routine blood monitoring. By combining a look at the patient's genetic instructions with regular checks of the actual drug levels in their blood, doctors can better personalize the treatment, ensuring the patient gets enough medicine to fight the infection without suffering from toxic side effects. This dual approach is essential for keeping high-risk patients safe, especially when they are taking multiple medications that interact with one another.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.